title: Activation of adenosine receptor potentiates the anticonvulsant effect of phenytoin against amygdala kindled seizures.
abstract: Drug resistance in epilepsy is considered as a complicated and multifactorial problem. Poor penetration of antiepileptic drugs (AEDs) across blood-brain barrier (BBB) into the brain, which results in insufficient level of the drugs at the targeted brain region, has been discussed as one mechanism contributing to pharmacoresistance of epilepsies. Therefore, modulating permeability of BBB is the effective treatment strategy since it facilitates the entry of AEDs into the central nervous system (CNS). Recently, signaling through receptors for the adenosine has been identified as a potent modulator of BBB permeability. This paper aimed to investigate the effects of auxiliary application of adenosine receptor (AR) agonist on amygdala-kindled seizures in adult male Wistar rats. When fully kindled seizures were achieved by daily electrical stimulation of the amygdala, rats were randomly divided into three groups: control, phenytoin, and phenytoin (PHT)+5'-N-ethylcarboxamidoadenosine (NECA) groups. NECA (0.08 mg/kg, i.v.) was applied to the PHT+NECA group after the administration of PHT (75 mg/kg, i.p. on the first day; 50mg/kg, i.p. on the following 9 days). Intravenous infusion of NECA resulted in a significant increase in brain PHT levels as compared with the PHT treatment alone. On the other hand, the auxiliary application of NECA dramatically decreased the frequency of generalized seizures and seizure stage, shortened duration of afterdischarge and generalized seizures, as well as the elevated the afterdischarge threshold and generalized seizures threshold. Our study demonstrated that auxiliary application of AR agonist enhanced brain antiepileptic drug levels and strengthened the anticonvulsant properties of PHT against amygdala kindled seizures.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Sun
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Zhong
authors.forename: Yu
authors.initials: Y
authors.lastname: Zong
authors.forename: Zhong-Chen
authors.initials: ZC
authors.lastname: Wu
authors.forename: Qun
authors.initials: Q
authors.lastname: Zhang
authors.forename: Jin-Tai
authors.initials: JT
authors.lastname: Yu
authors.affiliation: Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No.5 Donghai Middle Road, Qingdao 266071, PR China. dr.tanlan@163.com.
authors.forename: Lan
authors.initials: L
authors.lastname: Tan
mesh_terms: D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects* / Q000503:physiopathology; D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000494:pharmacology*; D004195:Disease Models, Animal; D004558:Electric Stimulation; D004569:Electroencephalography; D007696:Kindling, Neurologic / Q000187:drug effects / Q000502:physiology; D008297:Male; D010672:Phenytoin / Q000493:pharmacokinetics / Q000494:pharmacology*; D058906:Purinergic P1 Receptor Agonists / Q000494:pharmacology; D011897:Random Allocation; D017208:Rats, Wistar; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D012640:Seizures / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
chemical_list: D000927:Anticonvulsants; D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1; D019830:Adenosine-5'-(N-ethylcarboxamide); D010672:Phenytoin